A Closer Look At The New IDSA Guidelines For MRSA In Skin And Soft Tissue Infections

Warren S. Joseph DPM FIDSA
1/19/11 | 6550 reads | 0 comments
After an extended, deliberative writing and review process, the brand new Infectious Diseases Society of America (IDSA) clinical practice guidelines on the treatment of methicillin resistant Staphylococcus aureus (MRSA) have finally been published (full text at http://cid.oxfordjournals.org/content/early/2011/01/04/cid.ciq146.abstract ). Read More.

Questioning The Conventional Wisdom On Antibiotics And Prophylaxis

Warren S. Joseph DPM FIDSA
1/10/11 | 6612 reads | 0 comments
In my last blog (see http://bit.ly/eTSvDR ), I asked the readers for their opinions on antibiotic prophylaxis. Just as a recap, here are the clinical scenarios/questions that I posed. Read More.

Testing Your Knowledge On Antibiotic Prophylaxis: What Would You Do In These Cases?

Warren S. Joseph DPM FIDSA
12/13/10 | 4768 reads | 7 comments
With this blog entry, I am going to try something a bit different. I know that there is a good readership of my posts but, to date, I have been somewhat disappointed in the number of comments and interactions I have received from you, the readers. The whole idea of this blog is to be interactive. I want to hear others’ thoughts and ideas. Read More.

Will The FDA-Approved Ceftaroline Be Promoted To Podiatry?

Warren S. Joseph DPM FIDSA
11/8/10 | 4156 reads | 0 comments
As I expected and predicted in my previous blog, the FDA did not waste much time approving ceftaroline (Teflaro, Forest Laboratories) for complicated skin and skin structure infections (cSSSI). (See http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm231594.htm ). Read More.

Ceftaroline: A New Agent For cSSSIs?

Warren S. Joseph DPM FIDSA
10/12/10 | 4117 reads | 0 comments
For a number of years, many felt that ceftobiprole would be the first of the new so-called “fifth-generation” of anti-methicillin Staphylococcus aureus (MRSA) cephalosporins. This drug, a joint venture by the Swiss company Basilea Pharmaceutica and Johnson & Johnson, had come under some fire from the Food and Drug Administration (FDA) and now looks like it has pretty much been abandoned, at least here in the United States. Read More.

How A New Study Shows That Not All Vancomycin Is Created Equal

Warren S. Joseph DPM FIDSA
9/10/10 | 3670 reads | 0 comments
It is a rare study I read that literally makes me want to stop everything else I am doing and write a blog post about it. On a recent dreary, gray Sunday morning, I was just catching up on some backlogged journal reading when I picked up the August 2010 issue of Antimicrobial Agents and Chemotherapy. I came across a paper out of the University of Antioquia in Medellin, Colombia by Vesga and colleagues entitled “Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator.”1 (See http://aac.asm.org/cgi/content/abstract/54/8/3271 .) Read More.

Another Reason To Avoid Overuse Of Trimethoprim/ Sulfamethoxazole (TMP/SMX)

Warren S. Joseph DPM FIDSA
8/24/10 | 4689 reads | 0 comments
Those of you who have read my chapter on MRSA in the 3rd Edition of the Handbook of Lower Extremity Infections or listened to me lecture about MRSA know that I am less than happy with what I perceive to be the overuse of trimethoprim/sulfamethoxazole (TMP/SMX, Bactrim® or Septra®) used empirically against this bug. It seems to be first-line therapy by just about every emergency department, urgent care, primary care physician or anyone else treating skin and skin structure infections. Read More.

Questioning The Evidence Behind The Use Of Silver Dressings

Warren S. Joseph DPM FIDSA
7/30/10 | 3776 reads | 1 comments
A few months ago, Robert Kirsner, MD, PhD, and Stephanie Wu, DPM, invited me to write a chapter on “Antimicrobial Therapy” in their upcoming Wound Healing Society Yearbook. The design of the chapter is a review of a recently published primary study and two or more secondary studies. Read More.

What The Emerging Literature Reveals About Infection Control, Multi-Dose Vials And Surgical Centers

Warren S. Joseph DPM FIDSA
7/7/10 | 3540 reads | 0 comments
I know that this title seems like I am tying in a number of fairly diverse topics but hear me out on this one. I was browsing through USA Today while sitting in an airplane recently and came across a story titled "Safety Breaches at Surgery Centers". That in and of itself was interesting enough to me but upon reading the story, I learned that, “A federal study finds many same day surgery centers — where patients get such things as foot operations (my emphasis added) and pain injections — have serious problems with infection control.” Read More.